Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. - Wikidata - awgldk - TriplyDB

Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4.

Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4.

http://www.wikidata.org/entity/Q34343037

about

The Photobiology of Lutein and Zeaxanthin in the Eye Nutrient Supplementation for Age-related Macular Degeneration, Cataract, and Dry Eye A genetic dissection of intestinal fat-soluble vitamin and carotenoid absorption Dietary supplements and disease prevention - a global overview.Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study Visual acuity after cataract surgery in patients with age-related macular degeneration: age-related eye disease study 2 report number 5.Intravitreal use of bone marrow mononuclear fraction containing CD34+ stem cells in patients with atrophic age-related macular degeneration The Effect of a Mediterranean Diet on the Incidence of Cataract Surgery Press releases issued by supplements industry organisations and non-industry organisations in response to publication of clinical research findings: a case-control study.Nutritional modulation of cataract Inactivity of human β,β-carotene-9',10'-dioxygenase (BCO2) underlies retinal accumulation of the human macular carotenoid pigment.Topical nutraceutical Optixcare EH ameliorates experimental ocular oxidative stress in rats.Nutrition effects on ocular diseases in the aging eye.A dose-response meta-analysis of dietary lutein and zeaxanthin intake in relation to risk of age-related cataract.Ambiguities in dietary antioxidant supplementation compared to calcium channel blockers therapy.The Association of Dietary Lutein plus Zeaxanthin and B Vitamins with Cataracts in the Age-Related Eye Disease Study: AREDS Report No. 37 Estimating cumulative pathway effects on risk for age-related macular degeneration using mixed linear models.Lutein Leads to a Decrease of Factor D Secretion by Cultured Mature Human Adipocytes.Healthy Eating Index in Patients With Cataract: A Case-Control Study.The Association of Statin Use with Cataract Progression and Cataract Surgery: The AREDS2 Report Number 8 Evaluation of optimized digital fundus reflex photographs for lens opacities in the age-related eye disease study 2: AREDS2 report 7 'I'd like to know what causes it, you know, anything I've done?' Are we meeting the information and support needs of patients with macular degeneration? A qualitative study The Age-Related Macular Degeneration Complex: Linking Epidemiology and Histopathology Using the Minnesota Grading System (The Inaugural Frederick C. Blodi Lecture).Effects of multivitamin supplement on cataract and age-related macular degeneration in a randomized trial of male physicians.Antioxidant drug therapy approaches for neuroprotection in chronic diseases of the retina.The effect of multivitamin/mineral supplements on age-related cataracts: a systematic review and meta-analysis Recent developments in the treatment of age-related macular degeneration.Role of fatty acids and micronutrients in healthy ageing: a systematic review of randomised controlled trials set in the context of European dietary surveys of older adults.Risk factors and biomarkers of age-related macular degeneration.Carotenoids: biochemistry, pharmacology and treatment.Vitamin D and Age-Related Macular Degeneration.Ameliorative effects of SkQ1 eye drops on cataractogenesis in senescence-accelerated OXYS rats.Retinal accumulation of zeaxanthin, lutein, and β-carotene in mice deficient in carotenoid cleavage enzymes.The Evolving Role of Multivitamin/Multimineral Supplement Use among Adults in the Age of Personalized Nutrition.Recent Advances in Studies on the Therapeutic Potential of Dietary Carotenoids in Neurodegenerative Diseases.Lutein supplementation leads to decreased soluble complement membrane attack complex sC5b-9 plasma levels The Effect of Lutein on Eye and Extra-Eye Health

P2860

Q26769895-41C81C3C-6668-483A-89A1-626E97BA0397 Q26821899-4D9E3539-8191-4323-AE8C-56DD3EE4DAFA Q28512836-A11DBF43-6D7E-4C89-AF02-9BAF2AE0C3D3 Q30251418-6942BFA0-1916-4E30-98F7-82467800E312 Q30693939-DB86F49D-8546-401B-BD8B-29A4B1392389 Q33586908-37CDCE6D-ADD0-456F-BF12-27C1B0D43D42 Q33717538-BEF684CE-E78A-4C9F-9CDD-525A52608D5F Q33739755-9057E425-F5F4-4958-9D30-B89EC66A7DA2 Q33749282-3EBC753D-073C-4D7E-966A-7D3394096817 Q33845330-25E9F6FC-6623-4D44-93A8-4EC4236455AE Q33900780-DA39F7EC-D5BC-4E2B-9307-C780BCAA27EA Q33925653-DBE4E87D-9973-4177-A859-18B3473FB693 Q34116939-C6182649-40B8-47D2-8862-53A1AED0BD66 Q34132062-36FF116C-EC31-4159-810D-03C7F7D39683 Q34379644-64B5870E-A326-4280-8943-7880FE1F80C9 Q35042122-9D65B97B-9282-4ED9-9F8B-B95EC4241AEA Q35798037-9C274CDB-D112-402A-8088-F2A3FB8B4BE5 Q35807741-63F9D20B-5E04-430F-8C14-6999C87F1C8F Q36173190-D966A873-C48B-479C-BF6D-4C1ED82DD917 Q36266713-248F2CCB-4BC1-4379-9173-0D6A70CB740A Q36730429-9BBA672B-AE0E-48B5-A98E-05CD78108098 Q37166967-90DBEB9D-87E2-49A6-80CB-DACCE39FE002 Q37293286-0B8528E3-847F-4CEA-BDE0-C6AFC52E84BD Q37412560-099EB9D5-449D-4BD6-A0C1-B8A342B69894 Q37624757-12D7739A-4133-4D39-A7D4-CEE3BD61458C Q37645117-59DFB43F-E6B6-4768-8CD5-937A683C6939 Q37666797-6AFA5915-1461-4C58-9041-1E17FBA5099D Q37679956-F0244D58-0026-4168-B138-FEA5118ABBB3 Q38569301-8BB383F4-FDCC-423F-91E7-3541CFD3731E Q38828895-1E8C1EA3-F356-4D7C-9DAC-CDA8DCCD3502 Q38957329-5332A21A-DAC9-49A1-94F7-DC54C6CE7963 Q47100212-1A2E56D8-F676-4A2A-AAFA-0C38DEB3896C Q51048745-2A3CA543-55AD-401E-9F8E-3CE14B0F3247 Q52782567-623ED4E2-8264-4E3B-84C6-5D57A2ECD1A4 Q55224872-A052DD1E-8C18-4FE3-8EEE-73A5992B6378 Q55246756-B8081EAC-BD39-4E5D-8F16-8EE13B5FEC7C Q57337541-2512D86B-77A4-419A-A57D-21FC4C8AF71E Q58722677-23C38041-6BFE-4139-9430-940501802769

P2860

Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4.

http://www.wikidata.org/entity/Q34343037

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Lutein/zeaxanthin for the trea ...... randomized trial report no. 4.

@ast

Lutein/zeaxanthin for the trea ...... randomized trial report no. 4.

@en

Lutein/zeaxanthin for the trea ...... randomized trial report no. 4.

@nl

type

label

Lutein/zeaxanthin for the trea ...... randomized trial report no. 4.

@ast

Lutein/zeaxanthin for the trea ...... randomized trial report no. 4.

@en

Lutein/zeaxanthin for the trea ...... randomized trial report no. 4.

@nl

prefLabel

Lutein/zeaxanthin for the trea ...... randomized trial report no. 4.

@ast

Lutein/zeaxanthin for the trea ...... randomized trial report no. 4.

@en

Lutein/zeaxanthin for the trea ...... randomized trial report no. 4.

@nl

P1433

Q34343037-7E422B64-268B-48CE-8FF8-4BC7BD27E194

P1476

Q34343037-8AD553CF-755E-4920-A3BB-DEA27EDE09C2

P2093

Q34343037-023D2F39-890F-4ADC-9D28-4A7518F4CC43

Q34343037-0AF1C251-F78E-4588-A646-6DB71D343329

Q34343037-1C7E374C-DFBC-4FC6-BD18-5C65B35BB5A2

Q34343037-1E5D3FF6-8451-4728-B6ED-0D4FE7D48406

Q34343037-251E97D8-EB4C-4C46-B784-05B61FF3FAA4

Q34343037-2E87393B-4CC3-42FB-BF60-36515B93BD87

Q34343037-36B649FA-20F0-4124-AC78-B83CD74EC2F4

Q34343037-39192811-D39E-4F04-AFBC-3AAF04A2DC8B

Q34343037-4915A7B3-FFFD-4BB2-AD9B-43B442B5A022

Q34343037-5C93BE72-248D-4326-990F-04D64843A0DD

P304

Q34343037-B51BC5A5-E322-4E41-AE28-5C66575EFF41

P31

Q34343037-6DC1C976-7952-4B6F-9620-6AD83008AFD7

P356

Q34343037-FDDB9B22-7535-4696-9546-3D15436F1208

P407

Q34343037-8FDD2D3E-2C0E-421A-A3E6-E909DB7BD016

P433

Q34343037-B48AFFDD-C24C-48F8-A0E8-200A87597A16

P478

Q34343037-EA918E11-FD6C-42EB-8B0D-A5F15393E738

P50

Q34343037-2F0789CF-5938-4825-97B6-D817B6F58E22

Q34343037-47F81724-ACA7-4968-96FB-3A0CAE302D7F

P577

Q34343037-89659D36-BBDD-40D2-921B-3E8E838CB509

P5875

Q34343037-0D181DE0-804E-4FB8-842B-6241AE792C03

P698

Q34343037-2A6676FE-98A1-4F8C-81DF-E11FD5539181

P932

Q34343037-D9867D47-6023-4695-B6CB-682AAA21196F

P356

JAMAOPHTHALMOL.2013.4412

P1433

JAMA Ophthalmology

P1476

Lutein/zeaxanthin for the trea ...... randomized trial report no. 4

@en

P2093

Age-Related Eye Disease Study 2 (AREDS2) Research Group

http://www.w3.org/2001/XMLSchema#string

Alan J Ruby

http://www.w3.org/2001/XMLSchema#string

Amitha Domalpally

http://www.w3.org/2001/XMLSchema#string

Andrew N Antoszyk

http://www.w3.org/2001/XMLSchema#string

Barbara A Blodi

http://www.w3.org/2001/XMLSchema#string

Cynthia A Toth

http://www.w3.org/2001/XMLSchema#string

David Orth

http://www.w3.org/2001/XMLSchema#string

Elvira Agron

http://www.w3.org/2001/XMLSchema#string

Emily Y Chew

http://www.w3.org/2001/XMLSchema#string

Frederick L Ferris

http://www.w3.org/2001/XMLSchema#string

P304

843-850

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAOPHTHALMOL.2013.4412

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260945189

http://www.w3.org/2001/XMLSchema#string

P698

23645227

http://www.w3.org/2001/XMLSchema#string

P932

6774801

http://www.w3.org/2001/XMLSchema#string